Salvage allogeneic stem cell transplantation in patients with pediatric myelodysplastic syndrome and myeloproliferative neoplasms

Motohiro Kato, Nao Yoshida, Jiro Inagaki, Hideaki Maeba, Kazuko Kudo, Yuko Cho, Hidemitsu Kurosawa, Yuri Okimoto, Hisamichi Tauchi, Hiromasa Yabe, Akihisa Sawada, Koji Kato, Yoshiko Atsuta, Ken Ichiro Watanabe

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curable approach for myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN); however, the event-free survival rate of patients with pediatric MDS and MPN is still only approximately 60%. Although salvage HSCT is the only curative approach for patients with the failure of previous HSCT, its safety and efficacy have yet to be determined. Procedures: We retrospectively analyzed 51 pediatric MDS or MPN who received salvage HSCT for relapse or graft failure following HSCT using registry data of the Japan Society for Hematopoietic Cell Transplantation. The indications used for salvage HSCT were relapse in 22 patients and graft failure in 29 patients. Results: The overall survival (OS) rate for salvage HSCT in relapsed patients was 49.0±10.8% at 3 years. The cumulative incidence of relapse following salvage HSCT was 29.8±10.7% at 3 years, whereas the incidence of non-relapse mortality (NRM) was 28.6±10.2%. No significant differences were observed in the OS after salvage HSCT between disease types. Twenty-four of 29 patients who received salvage HSCT for graft failure achieved engraftment, resulting in an engraftment probability of 81.5±8.0% on day 100. The OS rate after salvage HSCT for graft failure was 56.8±9.6% at 3 years. Conclusions: Second HSCT should be considered as a valuable option for the patients with relapse and graft failure in patients with pediatric MDS or MPN after HSCT, but high NRM is an important issue that needs to be addressed.

Original languageEnglish
Pages (from-to)1860-1866
Number of pages7
JournalPediatric Blood and Cancer
Volume61
Issue number10
DOIs
Publication statusPublished - Oct 2014
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndromes
Stem Cell Transplantation
Pediatrics
Neoplasms
Transplants
Recurrence
Survival Rate
Mortality
Incidence
Cell Transplantation
Disease-Free Survival
Registries
Japan

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Salvage allogeneic stem cell transplantation in patients with pediatric myelodysplastic syndrome and myeloproliferative neoplasms. / Kato, Motohiro; Yoshida, Nao; Inagaki, Jiro; Maeba, Hideaki; Kudo, Kazuko; Cho, Yuko; Kurosawa, Hidemitsu; Okimoto, Yuri; Tauchi, Hisamichi; Yabe, Hiromasa; Sawada, Akihisa; Kato, Koji; Atsuta, Yoshiko; Watanabe, Ken Ichiro.

In: Pediatric Blood and Cancer, Vol. 61, No. 10, 10.2014, p. 1860-1866.

Research output: Contribution to journalArticle

Kato, M, Yoshida, N, Inagaki, J, Maeba, H, Kudo, K, Cho, Y, Kurosawa, H, Okimoto, Y, Tauchi, H, Yabe, H, Sawada, A, Kato, K, Atsuta, Y & Watanabe, KI 2014, 'Salvage allogeneic stem cell transplantation in patients with pediatric myelodysplastic syndrome and myeloproliferative neoplasms', Pediatric Blood and Cancer, vol. 61, no. 10, pp. 1860-1866. https://doi.org/10.1002/pbc.25121
Kato, Motohiro ; Yoshida, Nao ; Inagaki, Jiro ; Maeba, Hideaki ; Kudo, Kazuko ; Cho, Yuko ; Kurosawa, Hidemitsu ; Okimoto, Yuri ; Tauchi, Hisamichi ; Yabe, Hiromasa ; Sawada, Akihisa ; Kato, Koji ; Atsuta, Yoshiko ; Watanabe, Ken Ichiro. / Salvage allogeneic stem cell transplantation in patients with pediatric myelodysplastic syndrome and myeloproliferative neoplasms. In: Pediatric Blood and Cancer. 2014 ; Vol. 61, No. 10. pp. 1860-1866.
@article{e8a213b44c674124b8e18ee18ce6c553,
title = "Salvage allogeneic stem cell transplantation in patients with pediatric myelodysplastic syndrome and myeloproliferative neoplasms",
abstract = "Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curable approach for myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN); however, the event-free survival rate of patients with pediatric MDS and MPN is still only approximately 60{\%}. Although salvage HSCT is the only curative approach for patients with the failure of previous HSCT, its safety and efficacy have yet to be determined. Procedures: We retrospectively analyzed 51 pediatric MDS or MPN who received salvage HSCT for relapse or graft failure following HSCT using registry data of the Japan Society for Hematopoietic Cell Transplantation. The indications used for salvage HSCT were relapse in 22 patients and graft failure in 29 patients. Results: The overall survival (OS) rate for salvage HSCT in relapsed patients was 49.0±10.8{\%} at 3 years. The cumulative incidence of relapse following salvage HSCT was 29.8±10.7{\%} at 3 years, whereas the incidence of non-relapse mortality (NRM) was 28.6±10.2{\%}. No significant differences were observed in the OS after salvage HSCT between disease types. Twenty-four of 29 patients who received salvage HSCT for graft failure achieved engraftment, resulting in an engraftment probability of 81.5±8.0{\%} on day 100. The OS rate after salvage HSCT for graft failure was 56.8±9.6{\%} at 3 years. Conclusions: Second HSCT should be considered as a valuable option for the patients with relapse and graft failure in patients with pediatric MDS or MPN after HSCT, but high NRM is an important issue that needs to be addressed.",
author = "Motohiro Kato and Nao Yoshida and Jiro Inagaki and Hideaki Maeba and Kazuko Kudo and Yuko Cho and Hidemitsu Kurosawa and Yuri Okimoto and Hisamichi Tauchi and Hiromasa Yabe and Akihisa Sawada and Koji Kato and Yoshiko Atsuta and Watanabe, {Ken Ichiro}",
year = "2014",
month = "10",
doi = "10.1002/pbc.25121",
language = "English",
volume = "61",
pages = "1860--1866",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Salvage allogeneic stem cell transplantation in patients with pediatric myelodysplastic syndrome and myeloproliferative neoplasms

AU - Kato, Motohiro

AU - Yoshida, Nao

AU - Inagaki, Jiro

AU - Maeba, Hideaki

AU - Kudo, Kazuko

AU - Cho, Yuko

AU - Kurosawa, Hidemitsu

AU - Okimoto, Yuri

AU - Tauchi, Hisamichi

AU - Yabe, Hiromasa

AU - Sawada, Akihisa

AU - Kato, Koji

AU - Atsuta, Yoshiko

AU - Watanabe, Ken Ichiro

PY - 2014/10

Y1 - 2014/10

N2 - Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curable approach for myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN); however, the event-free survival rate of patients with pediatric MDS and MPN is still only approximately 60%. Although salvage HSCT is the only curative approach for patients with the failure of previous HSCT, its safety and efficacy have yet to be determined. Procedures: We retrospectively analyzed 51 pediatric MDS or MPN who received salvage HSCT for relapse or graft failure following HSCT using registry data of the Japan Society for Hematopoietic Cell Transplantation. The indications used for salvage HSCT were relapse in 22 patients and graft failure in 29 patients. Results: The overall survival (OS) rate for salvage HSCT in relapsed patients was 49.0±10.8% at 3 years. The cumulative incidence of relapse following salvage HSCT was 29.8±10.7% at 3 years, whereas the incidence of non-relapse mortality (NRM) was 28.6±10.2%. No significant differences were observed in the OS after salvage HSCT between disease types. Twenty-four of 29 patients who received salvage HSCT for graft failure achieved engraftment, resulting in an engraftment probability of 81.5±8.0% on day 100. The OS rate after salvage HSCT for graft failure was 56.8±9.6% at 3 years. Conclusions: Second HSCT should be considered as a valuable option for the patients with relapse and graft failure in patients with pediatric MDS or MPN after HSCT, but high NRM is an important issue that needs to be addressed.

AB - Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curable approach for myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN); however, the event-free survival rate of patients with pediatric MDS and MPN is still only approximately 60%. Although salvage HSCT is the only curative approach for patients with the failure of previous HSCT, its safety and efficacy have yet to be determined. Procedures: We retrospectively analyzed 51 pediatric MDS or MPN who received salvage HSCT for relapse or graft failure following HSCT using registry data of the Japan Society for Hematopoietic Cell Transplantation. The indications used for salvage HSCT were relapse in 22 patients and graft failure in 29 patients. Results: The overall survival (OS) rate for salvage HSCT in relapsed patients was 49.0±10.8% at 3 years. The cumulative incidence of relapse following salvage HSCT was 29.8±10.7% at 3 years, whereas the incidence of non-relapse mortality (NRM) was 28.6±10.2%. No significant differences were observed in the OS after salvage HSCT between disease types. Twenty-four of 29 patients who received salvage HSCT for graft failure achieved engraftment, resulting in an engraftment probability of 81.5±8.0% on day 100. The OS rate after salvage HSCT for graft failure was 56.8±9.6% at 3 years. Conclusions: Second HSCT should be considered as a valuable option for the patients with relapse and graft failure in patients with pediatric MDS or MPN after HSCT, but high NRM is an important issue that needs to be addressed.

UR - http://www.scopus.com/inward/record.url?scp=84908507012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908507012&partnerID=8YFLogxK

U2 - 10.1002/pbc.25121

DO - 10.1002/pbc.25121

M3 - Article

C2 - 24976435

AN - SCOPUS:84908507012

VL - 61

SP - 1860

EP - 1866

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 10

ER -